AzTrials
AzTrials

DeliriumNCT02673450

PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.

An observational study of Delirium, run by Zealand University Hospital at 1 site in Denmark.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This study investigates a possible relationship between disturbance of the cyclic expression of ten different clock genes and development of delirium in patients admitted to an intensive care unit It also investigates a possible relationship between disturbance of the cyclic expression of melatonin and development of… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Delirium
How many people
0 participants
Where
1 siteDenmark
Study dates
Sep 2018to Sep 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients admitted to the ICU at Køge Hospital in the study period

Who may be able to join

  • Patients >18 years of age admitted to the ICU at Køge Hospital in the study period

Who cannot join

  • Not able to speak or understand Danish
  • Melatonin (ATC N05CH01) or melatonin agonist (ATC N06AX) treatment prior to admission
  • Known insomnia (daily hypnotic (ATC N05C) consumption or known sleep disorder)
  • Patients discharged from the ICU during the test period (time from first to last blood sample)
  • Patients who die during the test period
  • Patients transferred to another hospital during ICU stay

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Zealand University Hospital

    Køge, 4600

Other trials in Denmark

About this study

Official title: PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit. A Prospective Cohort Study.

This study investigates a possible relationship between disturbance of the cyclic expression of ten different clock genes and development of delirium in patients admitted to an intensive care unit

It also investigates a possible relationship between disturbance of the cyclic expression of melatonin and development of delirium in patients admitted to an intensive care unit.

Finally a possible relationship between genetic differences in the PER3 gene and development of delirium is investigated.

Read the detailed description

An increasing number of patients are treated at ICUs worldwide. The majority of these patients survive critical illness and are discharged from hospital. In recent decades, improved therapy and survival at ICUs has increased focus on long term outcomes and post-ICU rehabilitation. Both physical and mental problems following admission for ICU therapy can be found for years after discharge. It is therefore important to discover factors that may have a significant impact for a worsened outcome, in order to prevent and treat these impairments.

Cognitive deficiencies may affect large proportions of the post intensive care population and mild cognitive impairment was demonstrated for up to 40% of the patients when evaluated three months after discharge. Recovery was slow and at one year follow up, 25% of the patients still showed impairment comparable to mild traumatic brain injury.

The presence of delirium during ICU stay has been associated with a worsened cognitive outcome at both 3 and 12 months follow up. Both patient's global cognition and especially executive function was impaired. Furthermore, a longer duration of the delirium period was associated with a poorer cognitive function. Incidence of delirium has also shown association to higher mortality rates and a longer hospital stay when compared to patients without delirium. In previous studies, the second day of admission has had the highest incidence of delirium.

Alterations in sleep architecture with a more shallow sleep and disruptions of the sleep wake cycle, is common in both ICU patients and patients with delirium. Sleep deprivation is often seen in delirious patients, and consequently, it has been suggested to be a risk factor for development of delirium.

The circadian rhythm is an inborn cycle of biological activity based on 24 hour intervals, and the rhythmicity interacts with sleep homeostasis in order to regulate sleep-wake cycles of individuals. In humans, the circadian rhythm is controlled by the suprachiasmatic nucleus (SCN) (the circadian clock) mediating melatonin secretion from the pineal gland to regulate the sleep-wake cycle. A number of factors, especially daylight, influence the SCN.

When blue light (460-480 nm wavelengths) reaches the retina and excites photoreceptors, it communicates with the pineal gland and secretion of melatonin is reduced to a minimum. Melatonin is secreted at night when blue light is absent and promotes sleep by activation of melatonin receptors. Melatonin secretion also interacts with a number of body functions, including core body temperature and the cardiac and immune systems. It is one of the key molecules in circadian rhythmicity. The circadian rhythm is not only affected by light, but is also synchronized by other factors, including shift work, artificial light exposure and exercise.

A number of genetic markers known as clock genes play a major role in the circadian control of different processes in the body. These genes may determine an individual's chronotype (morningness/eveningness), sensitivity to sleep disturbance and sleep deprivation, but much of their significance and function is still unknown.

A group of genes named PERIOD genes are shown to be involved in determining individual sleep wake regulation. PERIOD3 (PER3) is found in three subtypes: PER3 4/4, PER3 4/5 and PER3 5/5. The numbers refer to a variable number of tandem repeat polymorphism where a motif of 54 nucleotides is repeated for 4 or 5 U. Studies in large populations have shown 10% of individuals to be homozygous for the 5'-variation, 50% for the 4'-variation and 40% to be heterozygous.

Patients with homozygosity of the long allele (PER35/5) have more slow wave sleep and longer sleep duration compared to the other sub-types. Though no difference in melatonin or cortisol levels where seen, the two types reacted very differently to sleep deprivation. PER35/5 individuals performed poorly on a variety of cognitive tests compared to PER34/4. This information might help to identify subgroups of patients especially sensitive to development of delirium.

A recent study explored the relationship between PER3 genotype and postoperative cognitive dysfunction and did not find an association. The distribution of PER3 subtypes were as expected from previous studies. However, a possible association between PER 3 genotypes and cognitive dysfunction has never been investigated in ICU patients.

A number of other genes are involved in the circadian rhythm. These genes are expressed in a rhythmic manner following the natural light/dark cycle.

In healthy subjects, severely disturbed expression of the clock genes Clock, Cry1-2, Per1-3, Rorα, Bmal1, Rev-erb and CSNK1ε has been demonstrated after injection of endotoxin.

In septic ICU patients, a desynchronised expression of Cry-1 and Per-2 has been demonstrated. This disturbance was linked to secretion of proinflammatory cytokines as tumor necrosis factor α (TNFα) and interleukin 6 (IL-6).

The implication of the above is that if a disturbed circadian rhythm can be demonstrated to be associated with patients in delirium, we might in the future be able to identify patients with a higher risk of developing delirium - even in comatose or heavily sedated patients. Something which is not possible with the current diagnostic methods.

In this study, we therefore wish to investigate the relationship between PER3 gene polymorphism and incidence of delirium. This may help to identify patient groups at a higher risk of developing delirium and potentially prevent or treat these patients at an earlier stage.

The other objective is to identify differences in melatonin and cyclic gene expression in delirious patients, compared to other critically ill patients. This may be a new perspective for the diagnosis of delirium in heavily sedated patients.

Conditions
Delirium
Medical subject headings
Delirium

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clock gene expression

    Association between expression of clock genes (Clock, Cry1-2, Per1-3, Rorα, Bmal1, Rev-erb and CSNK1ε) (measured at 6am, 10am, 2pm, 6pm, 10pm and 2am) and incidence of delirium at the ICU

    Measured: 24 hours

Secondary outcomes (10)
  1. Melatonin secretion

    Association between secretion of melatonin at 6am, 10am, 2pm, 6pm, 10pm and 2am. Cosinor curve analysis (mesor, amplitude and acrophase) and incidence of delirium

    Measured: 24 hours

  2. PER3 subtype

    Association between PER3 subtype determination at 6am (PER3 4/4, PER3 4/5 and PER3 5/5) and incidence and duration of delirium

    Measured: 24 hours

  3. Delirium type

    Delirium type (hypoactive/hyperactive/mixed) associated to PER3 and expression pattern of clock genes and melatonin secretion

    Measured: 24 hours

  4. Demographic variables

    Age, gender, weight at admission associated to PER3 and expression pattern of clock genes and melatonin secretion

    Measured: 24 hours

  5. Sedation

    Infusion of propofol, dexmedetomidine, midazolam, sufentanil, remifentanil associated to PER3 and expression pattern of clock genes and melatonin secretion

    Measured: 24 hours

  6. Disease severity

    SAPS II score at admission associated to PER3 and expression pattern of clock genes and melatonin secretion

    Measured: 24 hours

  7. Admission type

    Type of admission (medical/acute surgical/elective surgical) associated to PER3 and expression pattern of clock genes and melatonin secretion

    Measured: 24 hours

  8. Length of stay

    Length of stay at ICU and hospital associated to PER3 and expression pattern of clock genes and melatonin secretion

    Measured: Up to 6 months

  9. Number of ventilator days

    Number of ventilator days at ICU and hospital associated to PER3 and expression pattern of clock genes and melatonin secretion

    Measured: Up to 6 months

  10. ICU delirium

    Delirium defined as positive CAM-ICU or treatment with antipsychotics

    Measured: Up to 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Feb 2016 (estimated)
  2. Study startSep 2018 (estimated)
  3. Primary completionSep 2020 (estimated)
  4. Study completionSep 2020 (estimated)

Why it stopped: Lack of lab ressources

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02673450
Sponsor's protocol ID
SE 2-16
Status last verified
Jan 2019
First submitted
1 Feb 2016
Last updated
10 Jan 2019
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Delirium, run by Zealand University Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 10 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clock gene expression (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2019; AzTrials last refreshed its copy on 31 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in